Cover Image
市場調查報告書

Teva Pharmaceutical Industries Limited的產品平台分析

Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 224553
出版日期 內容資訊 英文 150 Pages
訂單完成後即時交付
價格
Back to Top
Teva Pharmaceutical Industries Limited的產品平台分析 Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2016
出版日期: 2016年02月29日 內容資訊: 英文 150 Pages
簡介

Teva Pharmaceutical Industries Limited是從事非專利及品牌醫藥品的開發,製造,銷售的全球性製藥企業。

本報告提供Teva Pharmaceutical Industries Limited的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Teva Pharmaceutical Industries Limited的基本資料

Teva Pharmaceutical Industries Limited概要

  • 主要資訊
  • 企業資料

Teva Pharmaceutical Industries Limited:R&D概要

  • 主要的治療範圍

Teva Pharmaceutical Industries Limited:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
  • 轉出授權產品

Teva Pharmaceutical Industries Limited:開發中產品概況

  • 最後階段的開發中產品
  • 臨床實驗階段的開發中產品
  • 初期階段產品開發中產品

Teva Pharmaceutical Industries Limited:開發階段不明的開發中產品

Teva Pharmaceutical Industries Limited:藥物簡介

  • balugrastim
  • laquinimod sodium
  • lipegfilgrastim
  • DR-2011
  • armodafinil
  • beclomethasone dipropionate
  • bendamustine
  • custirsen sodium
  • hydrocodone bitartrate ER
  • Leukocyte Interleukin Injection
  • pridopidine
  • reslizumab
  • pagoclone
  • mercaptopurine DR
  • omacetaxine mepesuccinate
  • TV-1106
  • TV-1380
  • TV-45070
  • CEP-32496
  • CEP-37250
  • CEP-37440
  • CEP-9722
  • glatiramer acetate
  • irdabisant
  • rasagiline
  • XMT-1107
  • CEP-11981
  • CEP-28122
  • CEP-33779
  • CEP-37248
  • CEP-40783
  • NP-201
  • NP-202
  • AD-3
  • AD-4
  • 治療HIV用的固定劑量複方藥物
  • 治療中樞神經系統疾病用的小分子
  • 依賴症治療藥
  • 帕金森氏症治療藥
  • risperidone LAI等

Teva Pharmaceutical Industries Limited:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Teva Pharmaceutical Industries Limited:最近的開發平台趨勢

Teva Pharmaceutical Industries Limited:暫停中的計劃

Teva Pharmaceutical Industries Limited:開發中止的開發中產品

  • 開發中止的開發中產品簡介

Teva Pharmaceutical Industries Limited:企業發表

Teva Pharmaceutical Industries Limited:總公司和子公司的所地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07979CDB

Summary

Global Markets Direct's, 'Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2016', provides an overview of the Teva Pharmaceutical Industries Limited's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Teva Pharmaceutical Industries Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Teva Pharmaceutical Industries Limited
  • The report provides overview of Teva Pharmaceutical Industries Limited including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Teva Pharmaceutical Industries Limited's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Teva Pharmaceutical Industries Limited's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Teva Pharmaceutical Industries Limited's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Teva Pharmaceutical Industries Limited
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Teva Pharmaceutical Industries Limited's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Teva Pharmaceutical Industries Limited Snapshot
    • Teva Pharmaceutical Industries Limited Overview
    • Key Information
    • Key Facts
  • Teva Pharmaceutical Industries Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Teva Pharmaceutical Industries Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
    • Pipeline Products - Out-Licensed Products
  • Teva Pharmaceutical Industries Limited - Pipeline Products Glance
  • Teva Pharmaceutical Industries Limited - Late Stage Pipeline Products
  • Teva Pharmaceutical Industries Limited - Clinical Stage Pipeline Products
  • Teva Pharmaceutical Industries Limited - Early Stage Pipeline Products
  • Teva Pharmaceutical Industries Limited - Unknown Stage Pipeline Products
  • Teva Pharmaceutical Industries Limited - Drug Profiles
    • (fluticasone propionate + salmeterol xinafoate)
    • deutetrabenazine ER
    • hydrocodone bitartrate ER
    • laquinimod sodium
    • reslizumab
    • omacetaxine mepesuccinate
    • (acetaminophen + hydrocodone bitartarate) IR
    • armodafinil
    • beclomethasone dipropionate
    • bendamustine hydrochloride
    • fluticasone propionate
    • rasagiline mesylate
    • TEV-48125
    • funapide
    • pridopidine hydrochloride
    • TV-1380
    • (acetaminophen + oxycodone hydrochloride) IR
    • (fluticasone propionate + salmeterol xinafoate) MDI
    • CEP-37440
    • glatiramer acetate
    • SD-560
    • TEV-48107
    • TEV-90110
    • TEV-90111
    • TEV-90112
    • TEV-90113
    • TV-44664
    • atropine sulfate
    • CEP-11981
    • CEP-28122
    • CEP-33779
    • Drug for Undisclosed Indication
    • NIB-2
    • NP-201
    • NP-202
    • Recombinant Protein to Inhibit IL-17A for Psoriasis
    • Recombinant Protein to Target CD38 for Multiple Myeloma
    • SD-1077
    • Small Molecule 2 to Antagonize 5-HT6 for CNS Disorders
    • Small Molecule to Antagonize NMDA Receptor for Undisclosed Indication
    • Small Molecule to Inhibit CGRP for Migraine
    • Small Molecules to Inhibit DAT for Sleep Disorders
    • (acetaminophen + immediate release opioid 1)
    • (acetaminophen + immediate release opioid 2)
    • AD-3
    • AD-4
    • Fixed Dose Combination 3 for HIV
    • Fixed Dose Combination 4 for HIV
    • Small Molecule 1 to Antagonize 5-HT6 Receptor for CNS Disorders
    • Small Molecule to Inhibit PARP-1
    • Drug for Dependence
    • Drug for Parkinson's Disease
    • risperidone LAI
  • Teva Pharmaceutical Industries Limited - Pipeline Analysis
    • Teva Pharmaceutical Industries Limited - Pipeline Products by Target
    • Teva Pharmaceutical Industries Limited - Pipeline Products by Route of Administration
    • Teva Pharmaceutical Industries Limited - Pipeline Products by Molecule Type
    • Teva Pharmaceutical Industries Limited - Pipeline Products by Mechanism of Action
  • Teva Pharmaceutical Industries Limited - Recent Pipeline Updates
  • Teva Pharmaceutical Industries Limited - Dormant Projects
  • Teva Pharmaceutical Industries Limited - Discontinued Pipeline Products
  • Teva Pharmaceutical Industries Limited - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
  • Teva Pharmaceutical Industries Limited - Company Statement
  • Teva Pharmaceutical Industries Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Teva Pharmaceutical Industries Limited, Key Information
  • Teva Pharmaceutical Industries Limited, Key Facts
  • Teva Pharmaceutical Industries Limited - Pipeline by Indication, 2016
  • Teva Pharmaceutical Industries Limited - Pipeline by Stage of Development, 2016
  • Teva Pharmaceutical Industries Limited - Monotherapy Products in Pipeline, 2016
  • Teva Pharmaceutical Industries Limited - Combination Treatment Modalities in Pipeline, 2016
  • Teva Pharmaceutical Industries Limited - Partnered Products in Pipeline, 2016
  • Teva Pharmaceutical Industries Limited - Partnered Products/ Combination Treatment Modalities, 2016
  • Teva Pharmaceutical Industries Limited - Out-Licensed Products in Pipeline, 2016
  • Teva Pharmaceutical Industries Limited - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Teva Pharmaceutical Industries Limited - Pre-Registration, 2016
  • Teva Pharmaceutical Industries Limited - Filing rejected/Withdrawn, 2016
  • Teva Pharmaceutical Industries Limited - Phase III, 2016
  • Teva Pharmaceutical Industries Limited - Phase II, 2016
  • Teva Pharmaceutical Industries Limited - Phase I, 2016
  • Teva Pharmaceutical Industries Limited - Preclinical, 2016
  • Teva Pharmaceutical Industries Limited - Discovery, 2016
  • Teva Pharmaceutical Industries Limited - Unknown, 2016
  • Teva Pharmaceutical Industries Limited - Pipeline by Target, 2016
  • Teva Pharmaceutical Industries Limited - Pipeline by Route of Administration, 2016
  • Teva Pharmaceutical Industries Limited - Pipeline by Molecule Type, 2016
  • Teva Pharmaceutical Industries Limited - Pipeline Products by Mechanism of Action, 2016
  • Teva Pharmaceutical Industries Limited - Recent Pipeline Updates, 2016
  • Teva Pharmaceutical Industries Limited - Dormant Developmental Projects,2016
  • Teva Pharmaceutical Industries Limited - Discontinued Pipeline Products, 2016
  • Teva Pharmaceutical Industries Limited, Other Locations
  • Teva Pharmaceutical Industries Limited, Subsidiaries

List of Figures

  • Teva Pharmaceutical Industries Limited - Pipeline by Top 10 Indication, 2016
  • Teva Pharmaceutical Industries Limited - Pipeline by Stage of Development, 2016
  • Teva Pharmaceutical Industries Limited - Monotherapy Products in Pipeline, 2016
  • Teva Pharmaceutical Industries Limited - Combination Treatment Modalities in Pipeline, 2016
  • Teva Pharmaceutical Industries Limited - Partnered Products in Pipeline, 2016
  • Teva Pharmaceutical Industries Limited - Out-Licensed Products in Pipeline, 2016
  • Teva Pharmaceutical Industries Limited - Pipeline by Top 10 Target, 2016
  • Teva Pharmaceutical Industries Limited - Pipeline by Route of Administration, 2016
  • Teva Pharmaceutical Industries Limited - Pipeline by Molecule Type, 2016
  • Teva Pharmaceutical Industries Limited - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top